Show simple item record

dc.contributor.authorMinchom, A. R.en
dc.contributor.authorKrebs, Matthew Gen
dc.contributor.authorCho, B. C.en
dc.contributor.authorLee, S. H.en
dc.contributor.authorLeighl, N. B.en
dc.contributor.authorO'Neil, B.en
dc.contributor.authorSabari, J. K.en
dc.contributor.authorKudgus-Lokken, R.en
dc.contributor.authorAlhadab, A.en
dc.contributor.authorHaddish-Berhane, N.en
dc.contributor.authorZemlickis, D.en
dc.contributor.authorMitselos, A.en
dc.contributor.authorBerkay, E.en
dc.contributor.authorBauml, J. M.en
dc.contributor.authorKnoblauch, R. E.en
dc.contributor.authorHellemans, P.en
dc.contributor.authorJohnson, M. L.en
dc.date.accessioned2023-10-25T08:48:37Z
dc.date.available2023-10-25T08:48:37Z
dc.date.issued2023en
dc.identifier.citationMinchom AR, Krebs MG, Cho BC, Lee SH, Leighl NB, O'Neil B, et al. Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 dose. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003793.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.9126en
dc.identifier.urihttp://hdl.handle.net/10541/626657
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.9126en
dc.titleSubcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 doseen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDrug Development Unit at Royal Marsden Hospital/Institute of Cancer Research, Suttonen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record